Compare HSBC Holdings plc (HSBC) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HSBC Holdings plc vs BIO-TECHNE Corp — how do they compare? HSBC Holdings plc trades at $92.86 (market cap $311.92B), while BIO-TECHNE Corp trades at $72.45 (market cap $11.36B). The key difference: HSBC Holdings plc is far larger — about 27.5× BIO-TECHNE Corp's market cap, and HSBC Holdings plc pays the higher dividend (4.05%). Which is the better fit depends on your goals — on Pluang, investors hold HSBC Holdings plc for 36 Days and BIO-TECHNE Corp for 63 Days on average.
| HSBC | TECH | |
|---|---|---|
Market Cap | $311.92B | $11.36B |
Volume | 3,546,658 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $107.86 | $72.61 |
52-Week Low | $65.67 | $43.31 |
Typical Hold Time | 36 Days | 63 Days |
Enterprise Value | $222.19B | $11.39B |
Dividend Yield | 4.05% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HSBC trades at $92.80, down 0.97% with bearish technical signals. The stock shows strong profitability with 34.54% net margin and reasonable valuation at 13.23 P/E. Recent earnings were mixed with Q2 beat but Q1 miss. Analyst sentiment is cautious with 38% buy ratings. The bank is expanding in technology banking and US wealth services while restructuring European operations.
HSBC offers value with solid fundamentals but faces near-term headwinds from technical weakness and mixed earnings performance. Growth opportunities in Asian markets and wealth management balance risks from European restructuring and CFO transition in 2027.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
